---
document_datetime: 2023-09-21 20:51:53
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ozawade-epar-all-authorised-presentations_en.pdf
document_name: ozawade-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0790212
conversion_datetime: 2025-12-15 21:41:23.55516
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/21/1546/001 | OZAWADE           | 4.5 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets  |
| EU/1/21/1546/002 | OZAWADE           | 18 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 30 tablets  |
| EU/1/21/1546/003 | OZAWADE           | 18 mg      | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 90 tablets  |
| EU/1/21/1546/004 | OZAWADE           | 4.5 mg     | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 90 tablets  |